AngioDynamics Fourth Quarter and Full Year Earnings Presentation July 15, 2025 Forward-Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, ...

Carlsmed, a medical technology company that uses AI to personalize spine surgery, is seeking to raise as much as $107.2 million in a US IPO https://t.co/Z5je1FkV3q ...

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second quarter and full year 2025 MALVERN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients ...

CARLSBAD, California, July 15, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced it will be participating in the 7th Annual ASPN Conference sponsored by The American Society of Pain Neuroscience (ASPN) to be held July 17-20 at the Fontainebleu Miami Hotel in Miami Beach, Florida. Aurora will be located at Booth 129/130.To kick off the first full day of the ...

Core Insights - Cardinal Health plans to release its fourth-quarter and year-end financial results for fiscal year 2025 on August 12, prior to the opening of trading on the New York Stock Exchange [1] - A webcast discussion of these results will begin at 8:30 a.m. Eastern on the same day [1] Access Information - The webcast and corresponding slide presentation can be accessed via Cardinal Health's Investor Relations page without the need for an access code [2] - Presentation slides and a replay of the webcast will be available on the Investor Relations page for 12 months [2] Company Overview - Cardinal Health is a distributor of pharmaceuticals and specialty products, a global manufacturer and distributor of medical and laboratory products, and a supplier of home-health and direct-to-patient products and services [3] - The company operates nuclear pharmacies and manufacturing facilities and provides performance and data solutions [3] - Cardinal Health emphasizes a customer-centric focus that drives continuous improvement and leads to innovative solutions that enhance people's lives [3]

展览：2025年7月26日-29日 上海世博展览馆 WAIC 2025 世界人工智能大会 论坛：2025年7月26日-28日 上海世博中心 当人工智能以大模型、多智能体等技术形态加速重构医疗产业版图，从AI辅助诊断突破传统诊疗效率天花板，到加速AI药物研发候选化合物筛选周期， 技术革新正为全球医疗健康领域注入前所未有的想象空间。然而在技术狂飙的背后，产业落地的现实沟壑逐渐显现——从数据治理到临床转化，从技术伦 理到全球普惠，医疗AI在穿越实验室与真实世界的 "断层带" 时，正遭遇多重结构性矛盾的挑战。 在此背景下，2025世界人工智能大会暨人工智能全球治理高级别会议聚焦AI赋能医疗与健康，将从听、看两方面呈现。 「智听未来」 医疗与健康论坛矩阵 WAIC 2025医疗与健康板块设置4场重要论坛，将深度探讨AI赋能医疗健康的四大方向：诊疗范式创新、AI药物研发、AI临床应用、医疗普惠。 重点议题 AI在脑机接口领域的前沿探索 多智能体系统与人工智能未来走向 AI预测药物载体材料，提升靶向给药效率 基于人工智能的药品监管平台 智能药物递释系统 AI药物设计方法及新药研究 具身智能的实践探索与应用平台 基于人工智能 ...

预 填充 注射器是一种用于输送肠外给药的药品。预 填充 注射器（ Prefil Syringe ， Prefillable Syringe ）是指制造商已安装针头的单剂量疫苗包装。 预 填充 注射器是即用型一次性注射器，内含预先计量的剂量，可减少给药错误，提高患者依从性、给药准确性、便利性和安全性；提高患者生活 质量；并减少患者在诊所的就诊时间。本报告仅关注塑料预 填充 注射器（或称聚合物 PFS ）。 据 QYResearch 调研团队最新报告"全球塑料预填充注射器市场报告 2025-2031 "显示，预计 2031 年全球塑料预填充注射器市场规模将达到 19.2 亿美 元，未来几年年复合增长率 CAGR 为 6.0% 。 塑料预填充注射器 ，全球市场总体规模 全球 塑料预填充注射器 市场前 15 强生产商排名及市场占有率（基于 2 02 5 年调研数据；目前最新数据以本公司最新调研数据为准） 根据 QYResearch 头部企业研究中心调研，全球范围内塑料预填充注射器生产商主要包括 BD 、 Terumo 、 West Pharma 、 Gerresheimer 、 Schott 、 J.O.Pharma ...

学科建设与发展是提升诊疗服务能力的关键。为进一步促进乳腺学科建设与发展，中国临床肿瘤学会候任理事长、中国人民解放军总医院肿瘤医学部副 主任江泽飞建议，乳腺内外科的划分与发展应因地制宜。比如，大型肿瘤专科医院资源丰富、团队专业，应细化乳腺内外科，精准应对不同乳腺疾病，满足 患者多元化需求。而基层医疗机构资源有限，应按器官系统整合乳腺内外科资源，组建综合性诊疗团队，方便患者获得全面诊断和治疗。 据了解，为推进科研成果临床转化，助力癌症防控工作，激励广大医务人员修医德、行仁术，用优质的服务增进人民健康福祉，人民健康联合肿瘤防控 领域权威专家学者，于2020年启动了"人民好医生·金山茶花计划"，集中推荐展示了一批在肺癌、肝胆肿瘤、胃癌、食管癌、乳腺癌、妇科肿瘤、泌尿系统 肿瘤、淋巴瘤、鼻咽癌九大肿瘤防治领域做出突出贡献的中青年专家。 闫敏在学术交流现场。 郑州大学附属肿瘤医院乳腺科副主任、主任医师闫敏说："复发转移性乳腺癌患者目前受到的关注不够，全国各医疗机构中乳腺内科专科少，转移性乳 腺癌患者大多就诊乳腺癌外科或全肿瘤内科，对以全身药物治疗为主线，局部治疗为辅助的精准治疗、全程管理和长期生存重视不足，一定程度上影响 ...

Core Insights - PROCEPT BioRobotics Corporation announced that Aquablation therapy has been assigned a Category I CPT code effective January 1, 2026, marking a significant milestone for the company and the urology community [1][3] - The new Category I CPT code 52XX1 will replace the previous Category III CPT code 0421T and is associated with a proposed national average payment of approximately $540 under the 2026 Medicare Physician Fee Schedule [2][3] - The transition to a Category I code is expected to enhance surgeon adoption and increase patient access to Aquablation therapy, which offers durable symptom relief with a low risk of sexual side effects [3] Payment Structure - The 2026 proposed payment for Aquablation therapy is set at 16.14 total RVUs, compared to 15.82 total RVUs for TURP, which translates to an average payment of approximately $529 [3] - The Proposed Physician Fee Schedule was released on July 14, 2025, and will undergo a public comment period until September 2025, with a final rule expected in November 2025 [4] Aquablation Therapy Overview - Aquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet treatment for benign prostatic hyperplasia (BPH), providing personalized treatment planning based on real-time imaging [5][6] - The technology allows for precise removal of prostate tissue while preserving critical anatomy related to erectile and ejaculatory function, making it suitable for a wide range of patients [5][6] - BPH affects approximately 40 million men in the United States, highlighting the significant market potential for Aquablation therapy [6]

In the latest trading session, Doximity (DOCS) closed at $61.55, marking a +2.24% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.14%. On the other hand, the Dow registered a gain of 0.2%, and the technology-centric Nasdaq increased by 0.27%. Prior to today's trading, shares of the medical social networking site had gained 7.65% outpaced the Medical sector's loss of 1.34% and the S&P 500's gain of 3.97%.The investment community will be closely monitoring th ...